GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » Gross Margin %

GCTK (GlucoTrack) Gross Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. GlucoTrack's Gross Profit for the three months ended in Dec. 2024 was $0.00 Mil. GlucoTrack's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, GlucoTrack's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for GlucoTrack's Gross Margin % or its related term are showing as below:


GCTK's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 53.055
* Ranked among companies with meaningful Gross Margin % only.

GlucoTrack had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for GlucoTrack was 0.00% per year.


GlucoTrack Gross Margin % Historical Data

The historical data trend for GlucoTrack's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack Gross Margin % Chart

GlucoTrack Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlucoTrack Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlucoTrack's Gross Margin %

For the Medical Instruments & Supplies subindustry, GlucoTrack's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlucoTrack's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Gross Margin % distribution charts can be found below:

* The bar in red indicates where GlucoTrack's Gross Margin % falls into.


;
;

GlucoTrack Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

GlucoTrack's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )=Gross Profit (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

GlucoTrack's Gross Margin for the quarter that ended in Dec. 2024 is calculated as


Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


GlucoTrack  (NAS:GCTK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

GlucoTrack had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


GlucoTrack Gross Margin % Related Terms

Thank you for viewing the detailed overview of GlucoTrack's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlucoTrack Business Description

Traded in Other Exchanges
N/A
Address
301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
Executives
Drew Sycoff director C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
James S Cardwell officer: Chief Financial Officer CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter director 301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig director 301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps director C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
David Podwalski officer: Chief Commercial Officer 19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham director, officer: Chief Executive Officer 19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun officer: Chief Financial Officer 39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff director 1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Leslie Seff director PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Angela Strand Boydston director C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Eran Hertz officer: Chief Financial Officer C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich director C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100